Literature DB >> 31313392

Tropomodulin 3 modulates EGFR-PI3K-AKT signaling to drive hepatocellular carcinoma metastasis.

Hao Zheng1,2,3, Yuan Yang1,2,3, Yong-Gang Hong4, Meng-Chao Wang1,2,3, Sheng-Xian Yuan1,2,3, Zhen-Guang Wang1,2,3, Feng-Rui Bi5, Li-Qiang Hao4, Hong-Li Yan5, Wei-Ping Zhou1,2,3.   

Abstract

The mechanism of hepatocellular carcinoma (HCC) metastasis remains poorly understood. Tropomodulin 3 (TMOD3) is a member of the pointed end capping protein family that contributes to invasion and metastasis in several types of malignancies. It has been found to be crucial for the membranous skeleton and embryonic development, although, its role in HCC progression remains largely unclear. We observed increased levels of Tmod3 in HCCs, especially in extrahepatic metastasis. High Tmod3 expression correlated with aggressive carcinoma and poor patient with HCC survival. Loss-of-function studies conducted by us determined Tmod3 as an oncogene that promoted HCC growth and metastasis. Mechanistically, Tmod3 increases transcription of matrix metalloproteinase-2, -7, and -9 which required PI3K-AKT. Interaction between Tmod3 and epidermal growth factor receptor (EGFR) that supports the activation of EGFR phosphorylation, is essential for signaling activation of PI3K-AKT viral oncogene homolog. These findings reveal that Tmod3 enhances aggressive behavior of HCC both in vitro and in vivo by interacting with EFGR and by activating the PI3K-AKT signaling pathway.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  PI3K-AKT; epidermal growth factor receptor; hepatocellular carcinoma; metastasis; tropomodulin 3

Mesh:

Substances:

Year:  2019        PMID: 31313392     DOI: 10.1002/mc.23083

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  12 in total

1.  LncUBE2R2-AS1 acts as a microRNA sponge of miR-302b to promote HCC progression via activation EGFR-PI3K-AKT signaling pathway.

Authors:  Zhe Wu; Zhi-Hong Wei; Shao-Hua Chen
Journal:  Cell Cycle       Date:  2020-08-23       Impact factor: 4.534

2.  The Yunnan national medicine Maytenus compound inhibits the proliferation of hepatocellular carcinoma (HCC) by suppressing the activation of the EGFR-PI3K-AKT signaling pathway.

Authors:  Wen-Tao Zhao; Liu-Xin Han; Lin Liu; Bao-Zhen Zeng; Yi Zhang; Liu-Fang Zhao; Hong-Yan Hu; Jia-Wei Xia; Yi-Ze Li; Xu-Dong Xiang; Xiao-Lin Lin; Di Lu; Gao-Feng Li
Journal:  J Cancer       Date:  2021-04-07       Impact factor: 4.207

3.  METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner.

Authors:  Yuntao Shi; Yingying Zhuang; Jialing Zhang; Mengxue Chen; Shangnong Wu
Journal:  Cancer Manag Res       Date:  2020-12-23       Impact factor: 3.989

4.  Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.

Authors:  Xing Huang; Gang Zhang; Tianyu Tang; Tingbo Liang
Journal:  Mol Cancer       Date:  2021-03-01       Impact factor: 27.401

5.  Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell-Mediated Antitumor Activity.

Authors:  Hao Zheng; Wen-Juan Zheng; Zhen-Guang Wang; Yuan-Ping Tao; Zhi-Ping Huang; Le Yang; Liu Ouyang; Zhi-Qing Duan; Yi-Nuo Zhang; Bo-Ning Chen; Dai-Min Xiang; Gang Jin; Lu Fang; Fan Zhou; Bo Liang
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

6.  1‑Palmitoyl‑2‑linoleoyl‑3‑acetyl‑rac‑glycerol ameliorates EGF‑induced MMP‑9 expression by promoting receptor desensitization in MDA‑MB‑231 cells.

Authors:  Kwang Hoon Yang; Guen Tae Kim; Solji Choi; Sun Young Yoon; Jae Wha Kim
Journal:  Oncol Rep       Date:  2020-04-28       Impact factor: 3.906

7.  SKA3 Promotes Cell Growth in Breast Cancer by Inhibiting PLK-1 Protein Degradation.

Authors:  Li-Wei Ruan; Peng-Peng Li; Lang-Ping Jin
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

8.  SKA3 promotes lung adenocarcinoma metastasis through the EGFR-PI3K-Akt axis.

Authors:  Dan-Dan Hu; Hai-Ling Chen; Li-Ming Lou; Hong Zhang; Guo-Liang Yang
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

Review 9.  Cytoskeletal Remodeling in Cancer.

Authors:  Jaya Aseervatham
Journal:  Biology (Basel)       Date:  2020-11-07

Review 10.  Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer.

Authors:  Milad Ashrafizadeh; Mohammad Reza Bakhoda; Zahra Bahmanpour; Khandan Ilkhani; Ali Zarrabi; Pooyan Makvandi; Haroon Khan; Samaneh Mazaheri; Maryam Darvish; Hamed Mirzaei
Journal:  Front Chem       Date:  2020-10-15       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.